Ranibizumab for Neovascular Age-Related Macular Degeneration
2020 ◽
pp. 245-250
Keyword(s):
The Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) study was a randomized, double-blind, sham-controlled clinical trial to determine whether intravitreal administration of ranibizumab (an anti-vascular endothelial growth factor [VEGF] agent) prevents vision loss and improves mean visual acuity in patients with minimally classic or occult choroidal neovascularization related to age-related macular degeneration (AMD). Ranibizumab therapy was associated with clinically and statistically significant benefits in visual acuity and the amount of angiographic leakage from choroidal neovascularization during two years of follow-up, with low rates of serious adverse events.
2020 ◽
pp. 231-238
2013 ◽
Vol 5
◽
pp. CMT.S8921
◽
2010 ◽
Vol 6
(4)
◽
2018 ◽
Vol 103
(4)
◽
pp. 469-474
◽
1998 ◽
Vol 236
(5)
◽
pp. 321-325
◽
2020 ◽
Vol 77
(5)
◽
pp. 779-780
◽
2019 ◽
Vol 4
(1)
◽
pp. e000398
◽